|

Trifluridine/Tipiracil /Experimental Clinical Trials

1 actively recruiting trial

Also known as: LONSURF

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Health Research Institutes, Taiwan1

Indications

  • Second Line1
  • Metastatic Gastric Adenocarcinoma1
  • Chemotherapy1
  • Cancer1

Other1 trial

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.